2C-T-33

2C-T-33, also known as 4-(3-methoxybenzylthio)-2,5-dimethoxyphenethylamine, is a serotonin receptor agonist of the phenethylamine and 2C families.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

2C-T-33, also known as 4-(3-methoxybenzylthio)-2,5-dimethoxyphenethylamine, is a serotonin receptor agonist of the phenethylamine and 2C families.

Use and effects

2C-T-33 is not known to have ever been tested in humans and its active human doses have not been reported.

Pharmacodynamics

2C-T-33 shows high affinity for the serotonin 5-HT 2A receptor (K i = 1.7 nM) and to a much lesser extent for the serotonin 5-HT 2C receptor (K i = 75 nM; 44-fold lower than for 5-HT 2A ). In terms of serotonin 5-HT 2A receptor activation, its is 26 nM and its is 40%. Hence, 2C-T-33 acts as a low-efficacy partial agonist of the serotonin 5-HT 2A receptor.

The drug shows higher affinity for the serotonin 5-HT 2A receptor but much lower potency and efficacy in activating the receptor compared to 2C-T or 2C-B (which had values of K i = 6.9–49 nM, = 2.0–2.1 nM, and = 75–92%). In contrast to most other 2C drugs and serotonergic psychedelics, 2C-T-33 appears to be completely inactive as an agonist of the serotonin 5-HT 2B receptor ( > 10,000 nM).

The drug has also been assessed at a number of other targets. The drug did not significantly produce the head-twitch response (HTR), a behavioral proxy of psychedelic effects, in rodents, and hence may not have hallucinogenic effects in humans. Its analogue 2C-T-27 (which lacks the methoxy group on the added benzyl ring) significantly and potently induces the HTR in rodents.

However, the HTR induced by 2C-T-27 is far weaker in magnitude than that induced by other 2C-T-X drugs and other serotonergic psychedelics. For example, 2C-T (or 2C-T-1) induced about 7-fold more HTR events than 2C-T-33.

In contrast to the lack of assessment of 2C-T-33 in humans, 2C-T-27 has been evaluated and found to be active as a psychedelic in humans with a dose range of 80 to 130 mg. The lack of HTR with 2C-T-33 may be due to its low-efficacy partial agonism of the serotonin 5-HT 2A receptor and the receptor not being activated strongly enoughly.

The potencies of psychedelics in inducing the HTR are positively correlated with their efficacies in activating the serotonin 5-HT 2A receptor. The bulky 4 substitution of 2C-T-33 may be too large to accommodate the binding pocket of the serotonin 5-HT 2A receptor in terms of maintaining robust receptor activation.

Similar findings have been observed for other phenethylamines with bulky 4-position substitutions, such as DOHx, DOBz, and 4-PhPr-3,5-DMA. In addition to its potential psychoactive effects, 2C-T-33 has shown anti-inflammatory effects in animal studies similarly to other serotonin 5-HT 2A receptor agonists and serotonergic psychedelics.

However, 2C-T-33 was the least effective assessed phenethylamine and was far less effective than other phenethylamines such as 2C-I, DOIB, 2C-B, (R)-DOI, and 2,5-DMA, among others.

History

2C-T-33 was first synthesized and described by Daniel Trachsel in 2003.

Canada

2C-T-33 is a controlled substance in Canada under phenethylamine blanket-ban language.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1351487042 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.